Targets › FASN
2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Oncology, Other; next expected readout Dec 2026.
Fatty acid synthetase is a multifunctional enzyme that catalyzes the de novo biosynthesis of long-chain saturated fatty acids starting from acetyl-CoA and malonyl-CoA in the presence of NADPH. This multifunctional protein contains 7 catalytic activities and a site for the binding of the prosthetic group 4'-phosphopantetheine of the acyl carrier protein ([ACP]) domain..; FUNCTION: (Microbial infection) Fatty acid…. (UniProt, P49327)
Open in Phaseline: the race on FASN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| David E Gerber | TVB-2640 Fatty acid synthase (FASN) inhibitor | FASN | Phase 2 | KRAS Gene Mutation | Dec 2026 |
| Weill Medical College of Cornell University | TVB-2640 Fatty acid synthase (FASN) inhibitor | FASN | Phase 1 | Prostatic Neoplasms, Castration-Resistant | Jan 2028 |
Prostatic Neoplasms, Castration-Resistant (1) KRAS Gene Mutation (1)
small molecule (2)
Weill Medical College of Cornell University (1) David E Gerber (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.